A client focusing on several oncology treatments needed to determine the Economically Justifiable Price of their drug in a new indication. For this, it was necessary to input survival estimates into our model. However, at that point, we had not yet received survival estimates to produce realistic survival distributions.
The main challenge was to swiftly set up and perform a survival analysis on earlier data (i.e., Kaplan-Meier curves) provided by the client. For this project, we had agreed with the client that survival analysis would be performed by their statistical team and not ours. However, their statistical team was not able to produce the results at that time, and we had to perform the survival analysis ourselves in a limited timeframe.